You must be 21 years or older to access this website. All products are for research use only.
Are you 21 years of age or older?
By entering, you confirm that you are at least 21 years old and agree to our terms of service.
CJC-1295 / Ipamorelin · Published March 8, 2026 · Updated May 18, 2026 · 8 min read
CJC-1295 No DAC plus Ipamorelin engages two parallel pituitary signaling pathways: GHRH receptor activation via cAMP and ghrelin receptor activation via calcium. This guide explains the convergent somatotroph signaling, vesicle exocytosis dynamics, and research models that study the combination. For research use only, not for human consumption.
Research Use Only. All products are strictly for research use only (RUO). Not for human consumption. Products on this site are not intended to diagnose, treat, cure, or prevent any disease. These statements have not been evaluated by the FDA. By purchasing, you agree that you are a qualified researcher and that products will be used solely for in-vitro research purposes.
The CJC-1295 (No DAC) and Ipamorelin combination is a widely studied peptide blend in laboratory research focused on growth hormone-related signaling pathways. This blend is designed to allow researchers to investigate the interactions between multiple peptide mechanisms under controlled conditions, providing valuable insight into receptor activity and pathway coordination.
CJC-1295 is a synthetic 30-amino-acid analog of growth hormone-releasing hormone (GHRH). It is studied in research models as a long-acting GHRH receptor agonist that drives pulsatile growth hormone release from the pituitary.
CJC-1295 no-DAC activates the GHRH receptor (Gs/cAMP signaling), Ipamorelin activates the ghrelin receptor GHS-R1a (Gq/calcium signaling). Both converge on pituitary somatotrophs to drive synergistic exocytotic GH release.
Because it produces discrete pulsatile GH release rather than sustained elevation, the no-DAC form better preserves natural pulse architecture, which may matter for downstream signaling fidelity, receptor desensitization avoidance, and physiological accuracy in research models.
No. CJC-1295 is not approved by the FDA for any human therapeutic use. It is supplied strictly for in-vitro and preclinical research purposes by qualified investigators.
Key terms used in this article.
Continue exploring research insights and updates.
Research Use Only. All products are strictly for research use only (RUO). Not for human consumption. Products on this site are not intended to diagnose, treat, cure, or prevent any disease. These statements have not been evaluated by the FDA. By purchasing, you agree that you are a qualified researcher and that products will be used solely for in-vitro research purposes.
CJC-1295 (No DAC) is a synthetic analog of growth hormone-releasing hormone (GHRH), designed to stimulate pulsatile growth hormone release in a controlled manner. Ipamorelin, on the other hand, is a selective growth hormone secretagogue receptor (GHS-R) agonist that activates receptors independently. Studying these compounds together allows researchers to analyze overlapping and complementary effects on GH-related pathways.
When used in research, this blend allows detailed examination of multiple growth hormone-related pathways. CJC-1295 (No DAC) primarily triggers GHRH receptor signaling, while Ipamorelin activates GHS-R. Together, they enable researchers to study how simultaneous pathway activation influences downstream signaling, receptor sensitivity, and hormone release patterns in controlled laboratory experiments.
CJC-1295 without DAC is preferred in experiments requiring precise timing because it has a shorter half-life than the DAC-containing form. Researchers can design repeated-measure or time-sensitive protocols without prolonged receptor stimulation, enabling more detailed observation of signaling dynamics.
Ipamorelin's receptor selectivity makes it an ideal partner in combination studies. Its action is focused on GHS-R pathways, providing a cleaner readout when studying peptide interactions. Using both peptides together allows researchers to evaluate cooperative effects and better understand potential synergistic signaling mechanisms.
To maintain peptide integrity, proper handling and storage are critical. Both compounds are typically supplied as lyophilized powders. Researchers must follow established protocols to ensure consistent dosing, stability, and experimental reliability.
Using CJC-1295 (No DAC) and Ipamorelin together allows for a more nuanced understanding of growth hormone pathways. This approach provides insight into receptor coordination, timing effects, and potential synergistic interactions that are not observable when each peptide is tested alone.
Published research has explored dual-pathway activation mechanisms, with findings suggesting that combined receptor engagement offers enhanced understanding of coordinated signaling in laboratory settings.
At Midwest Peptide, our CJC-1295 (No DAC) and Ipamorelin combination is supplied with comprehensive quality documentation:
By combining CJC-1295 (No DAC) and Ipamorelin, researchers can design experiments that capture multiple facets of growth hormone signaling. This approach supports precise, controlled investigations that enhance reproducibility and deepen scientific understanding of peptide interactions.
For laboratories and research teams focused on growth hormone-related pathways, this peptide blend provides a reliable, research-compliant option for controlled in vitro experimentation.
The CJC-1295 No DAC mechanism centers on the growth hormone-releasing hormone receptor (GHRH-R), a class B G protein-coupled receptor expressed predominantly on anterior pituitary somatotrophs. Binding triggers Gαs coupling, activates adenylyl cyclase, and elevates intracellular cAMP. cAMP recruits protein kinase A (PKA), which phosphorylates the cAMP response element binding protein (CREB), driving induction of the pituitary-specific transcription factor Pit-1 and downstream GH gene transcription. Acute stimulation simultaneously releases preformed growth hormone from secretory granules through PKA-mediated phosphorylation of vesicle-associated proteins.
A high-resolution cryo-EM study (Zhou et al., Nature Communications, 2020) resolved the activated GHRH-Receptor in complex with Gs, showing how the N-terminal domain of the receptor cradles the alpha-helical GHRH ligand and how the transmembrane bundle reorganizes on activation. The substituted residues in CJC-1295 No DAC (positions 2, 8, 15, and 27) sit outside the receptor binding interface and preserve agonist activity while blocking the dipeptidyl peptidase-4 cleavage site at the N-terminus.
A parallel finding from the same pathway is that GHRH-R also engages Gβγ to activate the Ras/MAPK cascade, contributing to somatotroph proliferation beyond acute secretion. Investigators studying the long-term proliferative versus short-term secretory effects of GHRH analogs use this branch point to separate transcriptional from exocytotic readouts.
Ipamorelin acts on the growth hormone secretagogue receptor type 1a (GHSR-1a), a class A G protein-coupled receptor with notably high constitutive activity. Unlike acyl-ghrelin, which carries an octanoyl modification at serine 3 required for receptor binding, ipamorelin is a fully synthetic pentapeptide agonist designed to engage the same orthosteric pocket without the lipid moiety. Activated GHSR-1a couples primarily to Gαq/11, recruits phospholipase C, generates inositol trisphosphate (IP3) and diacylglycerol (DAG), and drives intracellular calcium mobilization from endoplasmic reticulum stores. The calcium signal triggers vesicle fusion and growth hormone release independently of the cAMP arm.
This is the molecular basis for the synergy observed when CJC-1295 No DAC and ipamorelin are co-administered in cultured pituitary preparations. Two independent receptors, two independent second messenger cascades (cAMP/PKA versus IP3/Ca2+), and a convergent exocytosis endpoint. The combined signal exceeds the linear sum of each individual stimulus because the calcium signal sensitizes the PKA-phosphorylated vesicle release machinery.
A peer-reviewed review of pituitary GH regulation (Fukushima et al., Frontiers in Endocrinology, 2021) maps how ghrelin-receptor signaling intersects with somatostatin tone, klotho-mediated modulation, and the GHRH pulse to produce the natural pulsatile pattern of growth hormone secretion. For laboratory studies modeling this pulsatility, the No DAC version of CJC-1295 is the relevant tool because its short half-life preserves the pulse shape rather than producing a flat tonic stimulus.
Beyond G protein coupling, GHSR-1a recruits both beta-arrestin 1 and beta-arrestin 2 in a phosphorylation-pattern-dependent manner (Bouzo-Lorenzo et al., Scientific Reports, 2016). The arrestin recruitment determines receptor internalization kinetics, downstream MAPK activation, and the duration of cellular responsiveness to repeated agonist exposure. This is the mechanistic explanation for receptor desensitization observed under sustained ghrelin-receptor stimulation, and it is directly relevant to experimental design in repeated-pulse protocols.
For laboratory researchers, the molecular detail above translates into concrete experimental choices. Studies isolating Gαs-mediated cAMP responses should use CJC-1295 No DAC alone with short measurement windows of 5 to 30 minutes post-dose, capturing peak cAMP accumulation before phosphodiesterase activity returns the signal to baseline. Studies focused on calcium-mediated exocytosis should use ipamorelin alone, with measurement of intracellular calcium by Fura-2 or Fluo-4 imaging across the first 60 to 120 seconds after agonist exposure.
Combination experiments are most informative when the temporal sequence is controlled. Pre-treatment with CJC-1295 No DAC followed 5 to 10 minutes later by ipamorelin allows the cAMP/PKA arm to fully prime the secretory machinery before the calcium signal triggers exocytosis, producing the largest measured GH release. Reversing the order, or co-applying both peptides simultaneously, generates a smaller but more physiologically representative response.
Receptor desensitization remains the principal confound in repeated-stimulation protocols. Recovery of full responsiveness requires a washout interval of at least 60 minutes for GHSR-1a (driven by beta-arrestin-mediated internalization) and approximately 20 to 30 minutes for GHRH-R. Interpreting dose-response curves without accounting for receptor recycling kinetics is one of the most common sources of irreproducible data in the published growth hormone literature.
Primary literature and topic hubs from peer-reviewed publishers covering this area of research:
Explore more peer-reviewed research and laboratory guides from our science team:
All products are third-party tested with a Certificate of Analysis (COA) included. For research use only.
Browse our full catalog of research-grade peptides. Every product is third-party tested with a COA included.
Browse ProductsMidwest Peptide supplies research-grade CJC-1295 with a Certificate of Analysis included for every batch, validated by HPLC purity and mass spectrometry identity testing.
The cheapest tirzepatide (GLP-2 TZ) for research is rarely the best value. Here is how to balance price against the analytical specifications that determine research utility.
May 5, 2026
